NCT02677324View on ClinicalTrials.gov

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

February 14, 2020

Study Completion Date

February 7, 2022

Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG

ABT199

Oral BCL-2 antagonist

Trial Locations (4)

10065

Weill Cornell Medical College, New York

91010

City of Hope National Medical Center, Duarte

94304

Stanford University, Palo Alto

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER